Mayne Pharma Group Limited (ASX:MYX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 398.10M |
| Revenue (ttm) | 413.53M |
| Net Income (ttm) | -129.23M |
| Shares Out | 81.25M |
| EPS (ttm) | -1.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 619,202 |
| Average Volume | 1,505,002 |
| Open | 4.99 |
| Previous Close | 4.90 |
| Day's Range | 4.96 - 5.10 |
| 52-Week Range | 3.74 - 7.31 |
| Beta | 1.08 |
| RSI | 40.63 |
| Earnings Date | May 27, 2025 |
About Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease the... [Read more]
Financial Performance
Financial StatementsNews
Cosette terminates $672m Mayne Pharma deal as legal challenge looms
The private-equity backed American giant began reviewing the deal two weeks ago because of concerns about its target’s financial performance since it first bid.
Why a private equity group is rethinking its bid for Mayne Pharma
Triggering a material adverse change clause is rare in M&A. It’s why Mayne should release Cosette’s letter on why it is reviewing its $672m bid.
Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal
Shares of Mayne Pharma plunged 30% on Wednesday after U.S.-based Cosette Pharmaceuticals initiated a review of its A$672 million ($432.1 million) acquisition, citing a "material adverse change" in the...
Mayne Pharma shares crash after suitor Cosette raises concerns
Shares in the drug company fell 30 per cent on Wednesday after its takeover suitor said there had been a material adverse change in its performance.
Mayne Pharma shares crash after suitor Cosette threatens to walk
Shares in the drug company fell 30 per cent on Wednesday after its takeover suitor said there had been a material adverse change in its performance.
ASX 200 LIVE: Mayne Pharma shares plunge; CBA hits record; JHX sales, earnings slip amid AZEK buy; ASIC sues Resimac, sharemarket rises
Shares lift; CBA resets intraday record, tops $176; Mayne Pharma-Cosette tie-up hangs in balance; Nufarm plunges; James Hardie drops 5pc. Follow live.
Disclosure doozy makes a mockery of Australia’s safe-haven fantasy
If you told a private-equity suitor about a regulatory headache, but not shareholders, was the event disclosable or not? A 15 per cent share price drop says Mayne Pharma got this one wrong.
Mayne Pharma Group reports 1H results
Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's ...
Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's Health Boosts Revenue and Profitability
Mayne Pharma expects earnings to triple, shares jump 24pc
Shares in volatile drugmaker Mayne Pharma jumped 24 per cent on Monday after the company said it expected stronger first-half earnings and revenues.
FEDERAL CONTRACEPTION PROPOSAL TO EXPAND ACCESS AND AFFORDABLE COVERAGE PAVES A STRONGER PATH FOR MAYNE PHARMA'S GROWTH IN WOMEN'S HEALTH
Proposed Ruling Aims to Eliminate Out-of-Pocket Costs for Contraception, Enhancing Access for Women in the United States ADELAIDE, Australia and RALEIGH, N.C. , Nov. 4, 2024 /PRNewswire/ -- Mayne Phar...
Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement
Mayne Pharma has filed a patent infringement lawsuit against Indian drugmaker Sun Pharma in a U.S. court, the Australian drugmaker said on Thursday.
Mayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call Transcript
Mayne Pharma Group Limited (OTCPK:MAYNF) Q2 2024 Results Conference Call February 25, 2024 5:00 PM ET